Evidence map›Paper›PMID 34049101›Full record

Trial reportDrug and alcohol dependence2021

Combined analysis of the moderating effect of a GRIK1 polymorphism on the effects of topiramate for treating alcohol use disorder.

Henry R Kranzler, Emily E Hartwell, Richard Feinn, Timothy Pond, Katie Witkiewitz, Joel Gelernter, Richard C Crist

2 registry-linked trialsOpen access · greenAbstract readRandomized Controlled TrialClinical Trial, Phase IIClinical Trial, Phase IV
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Drug and alcohol dependence, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00626925 phase4completednot on this map

Topiramate Treatment of Problem Drinkers

TypeinterventionalSponsorUConn HealthRan2008 to 2013Enrolled200ConditionsAlcohol DrinkingArmstopiramate, placebo
NCT02371889 phase2completednot on this map

A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers

TypeinterventionalSponsorUniversity of PennsylvaniaRan2014 to 2020Enrolled320ConditionsAlcoholism, Alcohol Use Disorder (AUD)ArmsTopiramate, Medical Management, Inactive Placebo
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. GRIK1 genotype and effect of topiramate for alcohol use: a systematic review.Journal of pharmaceutical health care and sciences · 2025
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Henry R KranzlerDepartment of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, United States; Mental Illness Research, Education and Clinical Center, Crescenz VAMC, United States. Electronic address: kranzler@pennmedicine.upenn.edu.
Emily E HartwellDepartment of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, United States; Mental Illness Research, Education and Clinical Center, Crescenz VAMC, United States.
Richard FeinnDepartment of Medical Sciences, Frank H. Netter School of Medicine at Quinnipiac University, North Haven, CT, 06473, United States.
Timothy PondDepartment of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, United States; Mental Illness Research, Education and Clinical Center, Crescenz VAMC, United States.
Katie WitkiewitzDepartment of Psychology, Center on Alcoholism, Substance Abuse, and Addictions, University of New Mexico, Albuquerque, NM, 87131, United States.
Joel GelernterDepartment of Psychiatry, Yale University School of Medicine and VA CT Healthcare Center, West Haven, CT, 06516, United States.
Richard C CristDepartment of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, United States.
Mental Illness Research, Education and Clinical Centers · USQuinnipiac University · USUniversity of New Mexico · USUniversity of Pennsylvania · USYale University · US

Funding

Vulnerabilities for coping-related drinking among post-college young adultsP60AA003510 · NIAAA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI BAUER, LANCE O. · 2008 to 2017
$17.5M
WHO COLLABORATIVE PROJECT ON MANAGEMENT OF HARMFUL ALCOHOL CONSUMPTIONP50AA003510 · NIAAA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI KRANZLER, HENRY RICHARD · 1985 to 2007
$13.6M
Pharmacogenetic Analysis of Topiramate Treatment of AUDR01AA023192 · NIAAA · UNIVERSITY OF PENNSYLVANIA · PI KRANZLER, HENRY RICHARD · 2014 to 2018
$2.7M
Mechanisms of Behavior Change in Alcohol Use Disorder TreatmentR01AA025539 · NIAAA · UNIVERSITY OF NEW MEXICO · PI TOFIGHI, DAVOOD, WITKIEWITZ, KATIE A · 2017 to 2021
$2.1M
NIAAA NIH HHS P50 AA003510NIAAA NIH HHS P60 AA003510NIAAA NIH HHS R01 AA023192NIAAA NIH HHS R01 AA025539
6 · The paper itself

Abstract

backgroundIn an initial study, we reported that topiramate reduced heavy drinking among individuals who sought to reduce their drinking and that the effect was moderated by a single nucleotide polymorphism (SNP; rs2832407) in GRIK1, which encodes the kainate GluK1 receptor subunit (Kranzler et al., 2014). In a subsequent study that prospectively randomized patients to medication group based on their rs2832407 genotype, we replicated the main effect of topiramate but not the moderating effect of the SNP (Kranzler et al., 2021). Given the similar design of the two studies, here we combined the findings to provide greater statistical power to test the pharmacogenetic effect. MATERIAL AND

methodsThis secondary analysis of two 12-week, randomized controlled trials of topiramate included a total of 292 European-ancestry individuals (67.1 % male; topiramate: 48.3 %, placebo: 51.7 %) with problematic alcohol use. Using MANOVA, we examined changes in self-reported alcohol consumption, problems resulting from alcohol use, and quality of life, and the biomarker γ-glutamyltransferase. To test the pharmacogenetic hypothesis, all patients were genotyped for rs2832407.

resultsThere was a significant overall effect of topiramate on the alcohol-related outcomes (partial η

conclusionsAlthough topiramate is an efficacious medication for reducing drinking and alcohol-related problems among patients with problematic alcohol use, rs2832407 does not appear to moderate its therapeutic effects. www.clinicaltrials.gov registrations: NCT00626925 and NCT02371889.

Indexed as

AlcoholismAlcohol DrinkingFemaleFructoseHumansMalePolymorphism, Single NucleotideQuality of LifeTopiramateFructoseTopiramateAlcohol use disorderHeavy drinkingPharmacogeneticsPharmacotherapyPrecision medicineTopiramate

Identifiers

PMID34049101
PMCPMC8282735
OpenAlexW3164638231

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.